A Web-based lifestyle intervention supports weight loss in patients with non-alcoholic fatty liver disease

April 13, 2018, European Association for the Study of the Liver

Patients with non-alcoholic fatty liver disease (NAFLD) who participated in a web-based lifestyle modification intervention achieved similar levels of weight loss and more rapid normalization of their liver enzymes than patients who participated in an intensive, group-based programme. The results of this Italian study, which were presented today at The International Liver Congress 2018 in Paris, France, also suggested that the degree of weight loss achieved by some patients in both intervention groups was likely to have resulted in fibrosis regression.

"We were impressed that more than one in 10 patients in both groups achieved a weight loss target of 10%", said Professor Giulio Marchesini from the University of Bologna, Italy, who presented the study findings. "This weight loss threshold has been associated with resolution of non-alcoholic steatohepatitis and regression of fibrosis in studies that have evaluated NAFLD histology."

NAFLD is the most common in Western countries and is characterized by excessive hepatic fat accumulation. The global prevalence of NAFLD has been estimated to have reached 25% of adults, and both genetic and lifestyle factors contribute to the pathogenesis of the disease. Lifestyle modifications geared towards weight loss, increased physical activity and improved dietary habits are central to the management of NAFLD, and structured intervention programmes are recommended in the guidelines.

"Lifestyle changes are mandatory for patients with NAFLD, but these are very difficult to achieve in busy clinical units," explained Prof. Marchesini. "We wanted to develop a web-based programme to help them achieve these changes, and to compare its effects with a structured, face-to-face programme involving a multidisciplinary team. The participation of patients with NAFLD in structured lifestyle programmes may be jeopardized by job and other time constraints, and a web-based intervention may be better suited to young, busy patients."

The study undertaken by Prof. Marchesini and colleagues included 716 patients with NAFLD. They either attended a 5-week intensive group-based lifestyle modification programme, created by a multidisciplinary team of physicians, dieticians and psychologists which encouraged a healthy diet and regular physical activity (n=438), or participated in a web-based intervention (n=278). The web-based programme included five modules, with interactive games, offline contact with the study centre, and questionnaires. Surrogate markers of NAFLD severity were tested at 6-, 12-, and 24-months of follow-up. The primary outcome measure for the study was the percentage of patients who achieved 10% weight loss.

According to Prof. Marchesini, body mass index decreased in both groups by almost 2 points, and the 10% weight loss target was achieved by 14% of all participants (12% of participants in the web-based intervention and 15% in the group-based intervention). All liver enzymes decreased significantly, irrespective of the intervention, but individuals in the web-based intervention were more likely than those in the group intervention to have a normal alanine aminotransferase (ALT) level at both 6 months (OR 2.34; 95% CI 1.27, 4.30) and 12 months (OR 2.22; 95% CI 1.33, 3.73). Surrogate markers of fibrosis decreased in both intervention groups, with statistically significant improvements from baseline observed in the Fibrosis-4 (FIB-4) index.

"Our study has shown that a web-based lifestyle modification programme is a feasible and practical way of achieving a clinically meaningful level of loss in our NAFLD patients," said Prof. Marchesini. "Ideally, we would now like to roll out the intervention to other liver units."

"Weight loss has long been recognized as an effective therapy for NAFLD, but the challenge has been creating the infrastructure to achieve it," said Prof. Phil Newsome from the Queen Elizabeth Hospital and University of Birmingham, Birmingham, UK, and EASL Governing Board Member. "Most studies have used conventional resource-intensive regimens which are not widely available in most clinical practices. This study by Prof. Marchesini demonstrates the potential of web-based approaches to achieve this at scale. The challenge now will be to see if are able to sustain the for longer periods of time."

Explore further: Guidelines updated for diagnosis, management of NAFLD

Related Stories

Guidelines updated for diagnosis, management of NAFLD

July 19, 2017
(HealthDay)—A practice guidance statement, published online July 17 in Hepatology, has been developed to augment the clinical practice guidelines for the diagnosis and management of non-alcoholic fatty liver disease (NAFLD).

Family of patients with NAFLD and cirrhosis are at increased risk of liver fibrosis

June 19, 2017
Non-alcoholic fatty liver disease (NAFLD) is a common disorder characterized by abnormal accumulation of fat in the liver. NAFLD is diagnosed in up to one in three adults and one in 10 children in the United States, and obesity ...

Waist not weight—the key to non-alcoholic fatty liver disease

April 16, 2016
A new study presented today demonstrates that a build-up of fat around the waist can cause more serious complications than obesity in the development of non-alcoholic fatty liver disease (NAFLD). The study was presented at ...

Recommendations developed for pediatric NAFLD

December 13, 2016
(HealthDay)—Evidence-based recommendations have been developed for screening, diagnosis, and treatment of pediatric nonalcoholic fatty liver disease (NAFLD). The guidelines were published online Nov. 30 in the Journal of ...

Physical activity reduces intrahepatic lipid content

October 4, 2016
(HealthDay)—For patients with nonalcoholic fatty liver disease (NAFLD) and underlying metabolic disorders, physical activity is associated with a reduction in intrahepatic lipid content and markers of hepatocellular injury, ...

Many diabetics don't know they have serious liver disease

September 21, 2015
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western world. NAFLD is a frequent finding in patients with type 2 diabetes, but the exact prevalence of NAFLD, as well as whether patients ...

Recommended for you

Infectious disease consultation significantly reduces mortality of patients with bloodstream yeast infections

October 17, 2018
In a retrospective cohort study conducted at the University of Alabama at Birmingham Division of Infectious Diseases, patients with candidemia—a yeast infection in the bloodstream—had more positive outcomes as they relate ...

Marker may help target treatments for Crohn's patients

October 16, 2018
Crohn's disease (CD), a chronic inflammatory condition of the intestinal tract, has emerged as a global disease, with rates steadily increasing over the last 50 years. Experts have long suspected that CD likely represents ...

Study traces hospital-acquired bloodstream infections to patients' own bodies

October 15, 2018
The most common source of a bloodstream infection acquired during a hospital stay is not a nurse's or doctor's dirty hands, or another patient's sneeze or visitor's cough, but the patient's own gut, Stanford University School ...

Polio: Environmental monitoring will be key as world reaches global eradication

October 15, 2018
Robust environmental monitoring should be used as the world approaches global eradication of polio, say University of Michigan researchers who recently studied the epidemiology of the 2013 silent polio outbreak in Rahat, ...

Researchers make essential imaging tests safer for people at risk of acute kidney injury

October 15, 2018
Every year, millions of people undergo medical tests and procedures, such as coronary angiography, which use intravascular contrast dyes. "For the majority of patients, these are safe and necessary procedures. However, about ...

Medical marijuana might help MS patients, but uncertainty remains

October 13, 2018
Medical products derived from marijuana might have a mild benefit in treating symptoms of multiple sclerosis, based on reports from patients.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.